Congenital hypothyroidism: a review of current diagnostic and treatment practices in relation to neuropsychologic outcome.
Because thyroid hormone is essential for normal brain development, children born with congenital hypothyroidism who lack thyroid hormone during a circumscribed period of early development are at risk of brain damage and mental retardation. Since the advent of newborn screening programs in the 1980s, the diagnosis and treatment of this condition are now provided in the first 2-3 weeks of birth in most regions. While this is usually sufficient to prevent mental retardation, the children so identified attain mildly reduced IQs from expectation, and may still experience subtle and specific neurocognitive deficits. Their particular deficits are related to the brief period of thyroid hormone insufficiency they undergo, especially factors reflecting the severity of hypothyroidism at the time of diagnosis, the duration of hypothyroidism in infancy, and thyroid hormones at time of testing. In this article, we review the specific kinds of deficits demonstrated by children with congenital hypothyroidism who were diagnosed by screening and treated early, as well as the factors associated with their disease and its management that contribute to these deficits. The disease-related factors that will be reviewed will include the etiology of hypothyroidism and severity of disease at the time of diagnosis, while the treatment-related factors will include age at onset of therapy, starting and subsequent dose levels, compliance, and treatment-adequacy issues. Also examined will be the effects of hormone levels at the time of testing. In addition, the role of moderating variables such as social, genetic, and environmental influences, as well as the child's gender, will be discussed. Furthermore, several new issues including the quality of subsequent management, ultimate outcome, and pregnancy will be additionally reviewed. In conclusion, while outcome in congenital hypothyroidism is substantially improved by screening, affected children do still experience mild neuropsychologic deficits. To reduce the impact of persisting deficits, further research is needed to determine the optimal starting dose for the different etiologies, guidelines for subsequent management, and alternative therapies. Moreover, now that the original samples are reaching adulthood and, in females, childbearing age, further research is also needed regarding treatment during pregnancy in women with congenital hypothyroidism, as is research to determine how this population ultimately fares in adulthood.
Rovet
Joanne
J
Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada. joanne.rovet@sickkids.ca
Daneman
Denis
D
D000367:Age Factors; D002657:Child Development; D002986:Clinical Trials as Topic; D003409:Congenital Hypothyroidism; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D007037:Hypothyroidism / Q000175:diagnosis* / Q000628:therapy*; D007231:Infant, Newborn; D008607:Intellectual Disability / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D015997:Neonatal Screening; D011247:Pregnancy; D011248:Pregnancy Complications / Q000517:prevention & control; D012737:Sex Factors; D013963:Thyroid Hormones / Q000097:blood; D016896:Treatment Outcome
D013963:Thyroid Hormones